AIMS: Angiotensin II (Ang II) has been shown to have both central and peripheral effects in mediating hypertension, for which the hypothalamic paraventricular nucleus (PVN) is an important brain cardio-regulatory centre. Angiotensin-converting enzyme 2 (ACE2) has been identified as a negative regulator of the pro-hypertensive actions of Ang II. Recent findings from our laboratory suggest that Ang II infusion decreases ACE2 expression in the PVN. In the present study, we hypothesized that ACE2 overexpression in the PVN will have beneficial effects in counteracting Ang II-induced hypertension. METHODS AND RESULTS: Male Sprague-Dawley rats were used in this study. Bilateral microinjection of an adenovirus encoding hACE2 (Ad-ACE2) into the PVN was used to overexpress ACE2 within this region. Mean arterial pressure measured by radiotelemetry was significantly increased after 14 days in Ang II-infused (200 ng/kg/min) rats vs. saline-infused controls (162.9 ± 3.6 vs. 102.3 ± 1.5 mmHg). Bilateral PVN microinjection of Ad-ACE2 attenuated this Ang II-induced hypertension (130.2 ± 5.7 vs. 162.9 ± 3.6 mmHg). ACE2 overexpression also significantly decreased AT(1)R and ACE expression and increased AT(2)R and Mas expression in the PVN. Additionally, ACE2 overexpression in the PVN attenuated the Ang II-induced increase in the expression of the pro-inflammatory cytokines tumour necrosis factor-α, interleukin (IL)-1β and IL-6 in the PVN. CONCLUSION: Our findings suggest that attenuation of pro-inflammatory cytokines in the PVN in combination with the shift of the renin-angiotensin system towards the anti-hypertensive axis (ACE2/Ang-(1-7)/Mas) may be responsible for the overall beneficial effects of ACE2 overexpression in the PVN on the Ang II-induced hypertensive response.
AIMS: Angiotensin II (Ang II) has been shown to have both central and peripheral effects in mediating hypertension, for which the hypothalamic paraventricular nucleus (PVN) is an important brain cardio-regulatory centre. Angiotensin-converting enzyme 2 (ACE2) has been identified as a negative regulator of the pro-hypertensive actions of Ang II. Recent findings from our laboratory suggest that Ang II infusion decreases ACE2 expression in the PVN. In the present study, we hypothesized that ACE2 overexpression in the PVN will have beneficial effects in counteracting Ang II-induced hypertension. METHODS AND RESULTS: Male Sprague-Dawley rats were used in this study. Bilateral microinjection of an adenovirus encoding hACE2 (Ad-ACE2) into the PVN was used to overexpress ACE2 within this region. Mean arterial pressure measured by radiotelemetry was significantly increased after 14 days in Ang II-infused (200 ng/kg/min) rats vs. saline-infused controls (162.9 ± 3.6 vs. 102.3 ± 1.5 mmHg). Bilateral PVN microinjection of Ad-ACE2 attenuated this Ang II-induced hypertension (130.2 ± 5.7 vs. 162.9 ± 3.6 mmHg). ACE2 overexpression also significantly decreased AT(1)R and ACE expression and increased AT(2)R and Mas expression in the PVN. Additionally, ACE2 overexpression in the PVN attenuated the Ang II-induced increase in the expression of the pro-inflammatory cytokines tumour necrosis factor-α, interleukin (IL)-1β and IL-6 in the PVN. CONCLUSION: Our findings suggest that attenuation of pro-inflammatory cytokines in the PVN in combination with the shift of the renin-angiotensin system towards the anti-hypertensive axis (ACE2/Ang-(1-7)/Mas) may be responsible for the overall beneficial effects of ACE2 overexpression in the PVN on the Ang II-induced hypertensive response.
Authors: Carlos Díez-Freire; Jorge Vázquez; María F Correa de Adjounian; Merari F R Ferrari; Lihui Yuan; Xeve Silver; Raquel Torres; Mohan K Raizada Journal: Physiol Genomics Date: 2006-06-20 Impact factor: 3.107
Authors: Fina Lovren; Yi Pan; Adrian Quan; Hwee Teoh; Guilin Wang; Praphulla C Shukla; Kevin S Levitt; Gavin Y Oudit; Mohammed Al-Omran; Duncan J Stewart; Arthur S Slutsky; Mark D Peterson; Peter H Backx; Josef M Penninger; Subodh Verma Journal: Am J Physiol Heart Circ Physiol Date: 2008-07-25 Impact factor: 4.733
Authors: Yumei Feng; Huijing Xia; Yanhui Cai; Carmen M Halabi; Lenice K Becker; Robson A S Santos; Robert C Speth; Curt D Sigmund; Eric Lazartigues Journal: Circ Res Date: 2009-11-19 Impact factor: 17.367
Authors: Vijay Koka; Xiao Ru Huang; Arthur C K Chung; Wansheng Wang; Luan D Truong; Hui Yao Lan Journal: Am J Pathol Date: 2008-04-10 Impact factor: 4.307
Authors: Lucas A C Souza; Caleb J Worker; Wencheng Li; Fatima Trebak; Trevor Watkins; Ariana Julia B Gayban; Evan Yamasaki; Silvana G Cooper; Bernard T Drumm; Yumei Feng Journal: Am J Physiol Heart Circ Physiol Date: 2019-03-29 Impact factor: 4.733
Authors: Fernando Pedro de Souza-Neto; Melissa Carvalho Santuchi; Mario de Morais E Silva; Maria José Campagnole-Santos; Rafaela Fernandes da Silva Journal: Curr Hypertens Rep Date: 2018-03-14 Impact factor: 5.369
Authors: Annette D de Kloet; Eric G Krause; Peng D Shi; Jasenka Zubcevic; Mohan K Raizada; Colin Sumners Journal: Pharmacol Ther Date: 2013-02-28 Impact factor: 12.310
Authors: Thyago M de Queiroz; Huijing Xia; Catalin M Filipeanu; Valdir A Braga; Eric Lazartigues Journal: Am J Physiol Heart Circ Physiol Date: 2015-08-07 Impact factor: 4.733